Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

Purpose Immunogenicity is a major reason for secondary loss of response to infliximab (IFX). Recent work suggested potentially lower immunogenicity of subcutaneous (SC) compared to intravenous (IV) IFX. However, it is unknown whether re-exposure to IFX SC after secondary loss of response and immunog...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of colorectal disease 2024-09, Vol.39 (1), p.151, Article 151
Hauptverfasser:	Husman, Julia, Černá, Karin, Matthes, Katja, Gilger, Maximilian, Arsova, Maia, Schmidt, Alexandra, Winzer, Nadia, Brosch, Anna-Magdalena, Brinkmann, Franz, Hampe, Jochen, Zeissig, Sebastian, Lukáš, Milan, Schmelz, Renate
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Adult Crohn Disease - drug therapy Crohn Disease - immunology Crohn's disease Feces - chemistry Female Gastroenterology Hepatology Humans Hypersensitivity (delayed) Hypersensitivity (immediate) Immunogenicity Infliximab Infliximab - administration & dosage Infliximab - immunology Infliximab - therapeutic use Injections, Subcutaneous Internal Medicine Intravenous administration Leukocyte L1 Antigen Complex - analysis Male Medical treatment Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Patients Proctology Remission Retrospective Studies Surgery Treatment Failure Tumor necrosis factor-α Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!